CRC Research Update

  • SCREENING

    Circulating microRNAs improve identification of high-risk adenomas in FIT-positive patients

    A Canadian study of 398 FIT-positive screening participants found that adding plasma microRNA analysis to baseline risk factors increased the ability to identify high-risk adenomas from an AUC of 0.61 to 0.82, achieving 95% sensitivity at a 20% threshold. (Cancer Epidemiol Biomarkers Prev)

  • TRIAL DATA

    Recurrence drives long-term prognosis after liver metastasis resection

    An international study of 3,002 patients who underwent hepatectomy for colorectal liver metastases found that 54% developed recurrence; multistate modeling showed that the probability of recurrence decreased the longer patients remained recurrence-free, and that recurrence was the dominant determinant of long-term prognosis. (Ann Surg Oncol)

  • RESEARCH

    Review maps immune resistance mechanisms in microsatellite-stable CRC

    A comprehensive review details how microsatellite-stable colorectal cancer, which accounts for approximately 85% of all CRC cases, exhibits limited responsiveness to immune checkpoint inhibitors through multiple mechanisms including low tumor mutational burden, WNT/β-catenin pathway activation, immunosuppressive cell accumulation, and metabolic alterations that impair immune cell function. (Front Oncol)

  • SCREENING

    AI colonoscopy systems show 20% increase in adenoma detection in meta-analyses

    Pooled data from meta-analyses confirms an approximately 20% relative increase in adenoma detection rate and an approximately 50% relative reduction in adenoma miss rate with computer-aided detection, with benefits most prominent for diminutive early lesions; cost-effectiveness modeling studies show ICERs ranging from EUR 23,000 to USD 122,539 per quality-adjusted life-year. (Transl Gastroenterol Hepatol)

🔬 Under 50 Spotlight

Research relevant to early-onset and younger CRC patients

  • National survey finds provider barriers to early-onset CRC diagnosis

    A national survey of 277 U.S. healthcare providers found that although 87% were concerned about early-onset colorectal cancer, approximately one-half reported that younger adults commonly experienced symptoms for four months or longer before seeking care, with the most frequently cited barriers including patients expecting symptoms to resolve (84%) and insurance and financial barriers (79%). (Dis Colon Rectum)

  • Surgically treated early-onset rectal neuroendocrine neoplasms increased from 234 to 778 cases annually

    A National Cancer Database analysis of 7,285 patients under 50 who underwent surgery for rectal neuroendocrine neoplasms found that annual cases increased from 234 in 2004 to 778 in 2023, with 91% undergoing local excision and 83% of tumors being low grade, compatible with increased detection of indolent lesions through greater endoscopic evaluation. (Am Surg)

Today's research spans screening advances, surgical outcomes, and the molecular underpinnings of treatment resistance in colorectal cancer.